Jump to content

Chlorthalidone

From Pharmacopedia
Revision as of 10:43, 23 May 2026 by MDElliottMD (talk | contribs) (home-claude category backfill (parser-claude gap closure))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Chlorthalidone
Thalitone; mostly prescribed generically

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Starting dose
12.5-25 mg PO once daily; titrate to 50 mg
Preparations
15 mg, 25 mg, 50 mg tablets
US FDA Max
100 mg/d (rarely used)
Pharmacology
Routes
Oral
Onset
Diuresis at 2-3 hours; BP effect over weeks
Duration
48-72 hours per dose (much longer than hydrochlorothiazide)
Half-life
40-60 hours (notable for the thiazide class)[1]
Bioavailability
~65% (oral)[1]
Pregnancy
Avoided where possible; same class concerns as HCTZ.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Chlorthalidone inhibits the Na+/Cl- cotransporter (NCC) in the distal convoluted tubule, producing the same natriuretic and vasodilatory effects as hydrochlorothiazide but with a substantially longer half-life that yields more sustained 24-hour BP control and modest evidence of better cardiovascular outcomes (ALLHAT, SHEP).0 Despite the favorable trial data, hydrochlorothiazide remains the dominant US thiazide prescription due to pricing and habit. Hyponatremia, hypokalemia, hypomagnesemia, hyperuricemia, hyperglycemia, and erectile dysfunction are characteristic class effects[1].

References

  1. 1.0 1.1 1.2 FDA Prescribing Information, chlorthalidone tablets, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012109s015lbl.pdf